Pathologic fractures correlate with reduced survival in patients with malignant bone disease

Data from randomized, controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease.

[1]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[2]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[3]  W. Dahut,et al.  Clodronate in the prevention and treatment of skeletal metastasis , 2005, Expert review of anticancer therapy.

[4]  L. Rosen,et al.  Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on prior history of skeletal complications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Col,et al.  Estimating Hip Fracture Morbidity, Mortality and Costs , 2003, Journal of the American Geriatrics Society.

[6]  F. Saad,et al.  Continuing benefit of zoledronic acid for the prevention of skeletal complications in men with advanced prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Cummings,et al.  Incident vertebral fractures and mortality in older women: a prospective study , 2003, Osteoporosis International.

[8]  B. Hillner,et al.  American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Bell,et al.  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Ohashi,et al.  Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Jb,et al.  Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. , 2005 .

[13]  K. Jaeggi,et al.  Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  G. Hortobagyi,et al.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Khuri,et al.  The Role of Bisphosphonates in the Management of Advanced Cancer with a Focus on Non-Small-Cell Lung Cancer , 2005, Oncology.

[16]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[17]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[18]  R. Pelger,et al.  Strategies for Management of Prostate Cancer-Related Bone Pain , 2001, Drugs & aging.

[19]  H. Bauer.  Controversies in the surgical management of skeletal metastases. , 2005, The Journal of bone and joint surgery. British volume.

[20]  M. Rodríguez García,et al.  Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. , 2005, Journal of nephrology.

[21]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[22]  L. Rosen,et al.  Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. , 2004, Clinical lung cancer.

[23]  M. Resnick,et al.  Skeletal fractures negatively correlate with overall survival in men with prostate cancer. , 2002, The Journal of urology.

[24]  T. Tanvetyanon.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2005, Cancer.

[25]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[26]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Hillner,et al.  American society of clinical oncology 2003 update on the role of biophosphonates and bone health issues in women with breast cancer , 2004 .

[28]  A. Howell,et al.  P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases , 2005 .

[29]  E. Truumees.  Medical consequences of osteoporotic vertebral compression fractures. , 2003, Instructional course lectures.

[30]  H. Hamdalla,et al.  Bone metastases. , 2000, Medicine and health, Rhode Island.

[31]  J. Kanis,et al.  Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  D. Roy,et al.  How many people develop fractures with what outcome? , 2005, Best practice & research. Clinical rheumatology.

[33]  F. Saad,et al.  Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. , 2004, European urology.

[34]  F. Khuri,et al.  The Role of Bisphosphonates in the Management of Advanced Cancer with a Focus on Non-Small-Cell Lung Cancer , 2005, Oncology.

[35]  K. Weinfurt,et al.  The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  M. Krzakowski,et al.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.